CARLOMAGNO, FRANCESCA
CARLOMAGNO, FRANCESCA
DIPARTIMENTO DI MEDICINA MOLECOLARE E BIOTECNOLOGIE MEDICHE
Molecular mechanisms of RET activation in human cancer
2002 Santoro, Massimo; Melillo, Rosa Marina; Carlomagno, F; Fusco, Alfredo; Vecchio, Giancarlo
Ret-mediated mitogenesis requires Src kinase activity.
1999 Melillo, Rosa Marina; Barone, Mv; Lupoli, G; Cirafici, Am; Carlomagno, F; Visconti, R; Matoskova, B; Di Fiore, Pp; Vecchio, G; Fusco, Alfredo; Santoro, Massimo
Efficient inhibition of RET/papillary thyroid carcinoma oncogenic kinases by 4-amino-5-(4-chloro-phenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine (PP2).
2003 Carlomagno, F; Vitagliano, D; Guida, T; Basolo, F; Castellone, Md; Melillo, ROSA MARINA; Fusco, Alfredo; Santoro, Massimo
The extent of linkage disequilibrium in four populations with distinct demographic histories
2000 Dunning, Am; Durocher, F; Healey, Cs; Teare, Md; Mcbride, Se; Carlomagno, Francesca; Xu, Cf; Dawson, E; Rhodes, S; Ueda, S; Lai, E; Luben, Rn; VAN RENSBURG, Ej; Mannermaa, A; Kataja, V; Rennart, G; Dunhami, ; Purvis, I; Easton, D; Ponder, Ba
Basi molecolari delle nuove terapie: inibitori delle protein-chinasi.
2007 Santoro, Massimo; Salvatore, G.; Carlomagno, F.; Fusco, Alfredo
Activation of RET oncogene and thyroid carcinogenesis
1993 Santoro, Massimo; Grieco, M.; Melillo, ROSA MARINA; Carlomagno, F.; Cerrato, A.; Sabino, N.; Battaglia, C.; Fusco, Alfredo; Vecchio, Giancarlo
The tyrosine kinase inhibitor ZD6474 blocks proliferation of RET mutant medullary thyroid carcinoma cells.
2011 Vitagliano, Donata; De Falco, V.; Tamburrino, Anna; Coluzzi, S.; Troncone, Giancarlo; Chiappetta, G.; Ciardiello, F; Tortora, G.; Fagin, J.; Ryan, A. J.; Carlomagno, Francesca; Santoro, Massimo
Ponatinib (AP24534) is a novel potent inhibitor of oncogenic RET mutants associated with thyroid cancer.
2013 De Falco, V; Buonocore, Preziosa; Muthu, M; Torregrossa, L; Basolo, F; Billaud, M; Gozgit, Jm; Carlomagno, Francesca; Santoro, Massimo
POINT MUTATION OF THE RET PROTO-ONCOGENE IN THE TT HUMAN MEDULLARY THYROID CARCINOMA CELL LINE
1995 Carlomagno, F.; Salvatore, Domenico; Santoro, M.; DE FRANCISCIS, V.; Quadro, L.; Panariello, L.; Colantuoni, V.; Fusco, Alfredo
Oncogenic rearrangements driving ionizing radiation-associated human cancer
2013 Santoro, Massimo; Carlomagno, Francesca
Identification of Polo-like kinase 1 as a potential therapeutic target in anaplastic thyroid carcinoma.
2009 Nappi, T.; Salerno, P.; Zitzelsberger, H.; Carlomagno, Francesca; Salvatore, G.; Santoro, Massimo
Receptor tyrosine kinase inhibitors in thyroid cancer.
2008 Castellone, Md; Carlomagno, Francesca; Salvatore, G; Santoro, Massimo
ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases
2002 Carlomagno, Francesca; Vitagliano, Donata; Guida, Teresa; Ciardiello, Fortunato; Tortora, Giampaolo; Vecchio, Giancarlo; Ryan, A. J.; Fontanini, G.; Fusco, Alfredo; Santoro, Massimo
Structure prediction and validation of the ERK8 kinase domain.
2013 Strambi, A; Mori, M; Rossi, M; Colecchia, D; Manetti, F; Carlomagno, Francesca; Botta, M; Chiariello, M.
Evolutionary conservation of the Eps8 gene and its mapping to human-chromosome 12q23-q24
1994 Wong, Wt; Carlomagno, Francesca; Druck, T; Barletta, C; Croce, Cm; Heubner, K; Kraus, Mh; DI FIORE, Pp
Frequent RET proto-oncogene mutations in multiple endocrine neoplasia type 2A
1994 Quadro, L; Panariello, L; Salvatore, D; Carlomagno, Francesca; Del Prete, M; Nunziata, V; Colantuoni, V; Di Giovanni, G; Brandi, Ml; Mannelli, M; Gheri, R; Verga, U; Libroia, A; Berger, N; Fusco, Alfredo; Grieco, M; Santoro, M.
Protein kinase Calpha activation by RET: evidence for a negative feedback mechanism controlling RET tyrosine kinase
2003 Melillo, ROSA MARINA; Carlomagno, Francesca; Oriente, F; Miele, C; Fiory, Francesca; Santopietro, S; Castellone, Md; Beguinot, F; Santoro, Massimo; Formisano, Pietro
Thyroid cancer in 2010: A roadmap for targeted therapies
2011 Carlomagno, Francesca; Santoro, Massimo
Ret-mediated mitogenesis requires Src kinase activity.
1999 Melillo, Rm; Barone, MARIA VITTORIA; Lupoli, G; Cirafici, Am; Carlomagno, F; Visconti, R; Matoskova, B; Di Fiore, Pp; Vecchio, G; Fusco, A; Santoro, M.
Potent mitogenicity of the RET/PTC3 oncogene correlates with its prevalence in tall-cell variant of papillary thyroid carcinoma
2002 F., Basolo; R., Giannini; C., Monaco; Melillo, ROSA MARINA; Carlomagno, Francesca; M., Pancrazi; G., Salvatore; G., Chiappetta; F., Pacini; R., Elisei; P., Miccoli; A., Pinchera; Fusco, Alfredo; Santoro, Massimo
| Titolo | Tipologia | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|---|
| Molecular mechanisms of RET activation in human cancer | 2.1 Contributo in volume (Capitolo o Saggio) | 2002 | Santoro, Massimo; Melillo, Rosa Marina; Carlomagno, F; Fusco, Alfredo; Vecchio, Giancarlo | |
| Ret-mediated mitogenesis requires Src kinase activity. | 1.1 Articolo in rivista | 1999 | Melillo, Rosa Marina; Barone, Mv; Lupoli, G; Cirafici, Am; Carlomagno, F; Visconti, R; Matoskova, B; Di Fiore, Pp; Vecchio, G; Fusco, Alfredo; Santoro, Massimo | |
| Efficient inhibition of RET/papillary thyroid carcinoma oncogenic kinases by 4-amino-5-(4-chloro-phenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine (PP2). | 1.1 Articolo in rivista | 2003 | Carlomagno, F; Vitagliano, D; Guida, T; Basolo, F; Castellone, Md; Melillo, ROSA MARINA; Fusco, Alfredo; Santoro, Massimo | |
| The extent of linkage disequilibrium in four populations with distinct demographic histories | 1.1 Articolo in rivista | 2000 | Dunning, Am; Durocher, F; Healey, Cs; Teare, Md; Mcbride, Se; Carlomagno, Francesca; Xu, Cf; Dawson, E; Rhodes, S; Ueda, S; Lai, E; Luben, Rn; VAN RENSBURG, Ej; Mannermaa, A; Kataja, V; Rennart, G; Dunhami, ; Purvis, I; Easton, D; Ponder, Ba | |
| Basi molecolari delle nuove terapie: inibitori delle protein-chinasi. | 2.1 Contributo in volume (Capitolo o Saggio) | 2007 | Santoro, Massimo; Salvatore, G.; Carlomagno, F.; Fusco, Alfredo | |
| Activation of RET oncogene and thyroid carcinogenesis | 2.1 Contributo in volume (Capitolo o Saggio) | 1993 | Santoro, Massimo; Grieco, M.; Melillo, ROSA MARINA; Carlomagno, F.; Cerrato, A.; Sabino, N.; Battaglia, C.; Fusco, Alfredo; Vecchio, Giancarlo | |
| The tyrosine kinase inhibitor ZD6474 blocks proliferation of RET mutant medullary thyroid carcinoma cells. | 1.1 Articolo in rivista | 2011 | Vitagliano, Donata; De Falco, V.; Tamburrino, Anna; Coluzzi, S.; Troncone, Giancarlo; Chiappetta, G.; Ciardiello, F; Tortora, G.; Fagin, J.; Ryan, A. J.; Carlomagno, Francesca; Santoro, Massimo | |
| Ponatinib (AP24534) is a novel potent inhibitor of oncogenic RET mutants associated with thyroid cancer. | 1.1 Articolo in rivista | 2013 | De Falco, V; Buonocore, Preziosa; Muthu, M; Torregrossa, L; Basolo, F; Billaud, M; Gozgit, Jm; Carlomagno, Francesca; Santoro, Massimo | |
| POINT MUTATION OF THE RET PROTO-ONCOGENE IN THE TT HUMAN MEDULLARY THYROID CARCINOMA CELL LINE | 1.1 Articolo in rivista | 1995 | Carlomagno, F.; Salvatore, Domenico; Santoro, M.; DE FRANCISCIS, V.; Quadro, L.; Panariello, L.; Colantuoni, V.; Fusco, Alfredo | |
| Oncogenic rearrangements driving ionizing radiation-associated human cancer | 1.1 Articolo in rivista | 2013 | Santoro, Massimo; Carlomagno, Francesca | |
| Identification of Polo-like kinase 1 as a potential therapeutic target in anaplastic thyroid carcinoma. | 1.1 Articolo in rivista | 2009 | Nappi, T.; Salerno, P.; Zitzelsberger, H.; Carlomagno, Francesca; Salvatore, G.; Santoro, Massimo | |
| Receptor tyrosine kinase inhibitors in thyroid cancer. | 1.1 Articolo in rivista | 2008 | Castellone, Md; Carlomagno, Francesca; Salvatore, G; Santoro, Massimo | |
| ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases | 1.1 Articolo in rivista | 2002 | Carlomagno, Francesca; Vitagliano, Donata; Guida, Teresa; Ciardiello, Fortunato; Tortora, Giampaolo; Vecchio, Giancarlo; Ryan, A. J.; Fontanini, G.; Fusco, Alfredo; Santoro, Massimo | |
| Structure prediction and validation of the ERK8 kinase domain. | 1.1 Articolo in rivista | 2013 | Strambi, A; Mori, M; Rossi, M; Colecchia, D; Manetti, F; Carlomagno, Francesca; Botta, M; Chiariello, M. | |
| Evolutionary conservation of the Eps8 gene and its mapping to human-chromosome 12q23-q24 | 1.1 Articolo in rivista | 1994 | Wong, Wt; Carlomagno, Francesca; Druck, T; Barletta, C; Croce, Cm; Heubner, K; Kraus, Mh; DI FIORE, Pp | |
| Frequent RET proto-oncogene mutations in multiple endocrine neoplasia type 2A | 1.1 Articolo in rivista | 1994 | Quadro, L; Panariello, L; Salvatore, D; Carlomagno, Francesca; Del Prete, M; Nunziata, V; Colantuoni, V; Di Giovanni, G; Brandi, Ml; Mannelli, M; Gheri, R; Verga, U; Libroia, A; Berger, N; Fusco, Alfredo; Grieco, M; Santoro, M. | |
| Protein kinase Calpha activation by RET: evidence for a negative feedback mechanism controlling RET tyrosine kinase | 1.1 Articolo in rivista | 2003 | Melillo, ROSA MARINA; Carlomagno, Francesca; Oriente, F; Miele, C; Fiory, Francesca; Santopietro, S; Castellone, Md; Beguinot, F; Santoro, Massimo; Formisano, Pietro | |
| Thyroid cancer in 2010: A roadmap for targeted therapies | 1.1 Articolo in rivista | 2011 | Carlomagno, Francesca; Santoro, Massimo | |
| Ret-mediated mitogenesis requires Src kinase activity. | 1.1 Articolo in rivista | 1999 | Melillo, Rm; Barone, MARIA VITTORIA; Lupoli, G; Cirafici, Am; Carlomagno, F; Visconti, R; Matoskova, B; Di Fiore, Pp; Vecchio, G; Fusco, A; Santoro, M. | |
| Potent mitogenicity of the RET/PTC3 oncogene correlates with its prevalence in tall-cell variant of papillary thyroid carcinoma | 1.1 Articolo in rivista | 2002 | F., Basolo; R., Giannini; C., Monaco; Melillo, ROSA MARINA; Carlomagno, Francesca; M., Pancrazi; G., Salvatore; G., Chiappetta; F., Pacini; R., Elisei; P., Miccoli; A., Pinchera; Fusco, Alfredo; Santoro, Massimo |